Tissue Regenix Group PLC (LON:TRX) has said first delivery of its new OrthoPure XT product has taken place with further orders expected to be shipped early next year.
The regenerative medicines specialist noted that this represents a quick turnaround from approval (it received its CE Mark in June) to the sale of the first decellularized tendons.
Interest in Tissue’s technology was such that it landed its first UK order in August with a speciality supplier of orthopaedic and biologic products.
It has since targeted Europe, securing a partner in Poland, and is currently in discussions with other parties.
"Our plan is to establish an initial distribution network for OrthoPure XT and expand as procedural levels return,” said Tissue Regenix chief executive Daniel Lee in a statement.
“This will be a key product for the group in Europe and highlights the need, and demand, for biologic solutions outside of the current US market. It is a testament to the work of our processing and commercial teams that we have secured distribution agreements and delivery of the product has remained on-track despite the challenges presented during 2020," he added.
OrthoPure XT, which incorporates the company’s dCELL technology, is used in knee ligament reconstruction.